Rezolute is a late-stage rare disease biopharmaceutical company focused on developing transformative therapies for patients living with severe metabolic and endocrine disorders. Our mission is to bring hope and meaningful solutions to patients and families affected by rare and difficult-to-treat diseases through scientific innovation, collaboration, and integrity.

Rezolute’s lead investigational therapy, RZ358 (ersodetug), is a fully human monoclonal antibody in late-stage clinical development for the treatment of hypoglycemia due to congenital and acquired forms of hyperinsulinism (HI). As Rezolute expands its medical and scientific focus into tumor-related hyperinsulinism (tumor HI), most commonly related to pancreatic neuroendocrine tumors (insulinomas) or paraneoplastic hypoglycemia (NICTH), the company is committed to advancing novel therapeutic strategies that address this rare and complex form of hypoglycemia associated with insulin-secreting tumors and related neuro-oncology disorders.

Position Summary

The Medical Director, Medical Affairs (Sr. Director- Executive Director) will serve as Rezolute’s internal medical and scientific expert in Endocrine-Oncology. This individual will play a pivotal role in developing and executing the Medical Affairs strategy that bridges oncology and endocrinology, advancing understanding and awareness of hypoglycemia in oncologic conditions.

This role will lead internal disease-state and product education, guide cross-functional launch readiness, and provide scientific leadership for engagement with oncology and endocrinology key opinion leaders (KOLs). The Medical Director will partner closely with field-based Senior Medical Science Liaisons (MSLs) and colleagues across Clinical Development, Regulatory Affairs, Commercial, and Market Access to ensure scientific excellence, alignment, and execution across all medical initiatives. This position wil report to the Chief Medical Officer

Key Responsibilities